58960-11-5

Basic information

• Product Name: 6-METHOXY-3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE
• Synonyms: 6-METHOXY-3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE HYDROCHLORIDE;6-METHOXY-3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE;6-Methoxy-3,4-dihydro-2H-1,4-benzoxazine, 97%;AKOS BC-1148
• CAS NO: 58960-11-5
• Molecular Formula: C₉H₁₁NO₂
• Molecular Weight: 165.19
• Product Categories: pharmacetical
• Mol File: 58960-11-5.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 279.543 °C at 760 mmHg
• Flash Point: 106.01 °C
• Appearance: /
• Density: 1.121 g/cm³
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.529
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-METHOXY-3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHOXY-3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE(58960-11-5)
• EPA Substance Registry System: 6-METHOXY-3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE(58960-11-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 58960-11-5(Hazardous Substances Data)

Usage

General Description

6-Methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazine, also known as H2BO, is a chemical compound with the molecular formula C9H11NO2. It is a heterocyclic compound that consists of a benzene ring fused with a 1,4-oxazine ring. 6-Methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazine is an organic compound with a methoxy group (CH3O-) attached to the 6th carbon of the benzene ring. 6-Methoxy-3,4-dihydro-2H-benzo[b][1,4]oxazine has potential applications in pharmaceuticals, organic synthesis, and material science due to its unique structure and properties. Its heterocyclic structure and oxygen-containing functional groups make it a versatile compound with potential uses in various fields.

InChI:InChI=1/C9H11NO2/c1-11-7-2-3-9-8(6-7)10-4-5-12-9/h2-3,6,10H,4-5H2,1H3

Upstream product

• 20734-76-3 2-amino-4-methoxyphenol 
• 106-93-4 ethylene dibromide 
• 1568-70-3 4-methoxy-2-nitrophenol 
• 5023-12-1 6-methoxy-2H-benzo[b][1,4]oxazin-3(4H)-one 

Downstream Products

• 26438-50-6 4-ethyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-ol 
• 26021-57-8 3,4-dihydro-6-hydroxy-1,4(2H)-benzoxazine 
• 1338594-89-0 3-(6-methoxy-2,3-dihydrobenzo[1,4]oxazin-4-yl)-3-methylsulfanyl-1-phenylpropenone 
• 1338594-95-8 C₁₉H₁₇NO₃ 
• 1202503-66-9 4-(2,4-dichlorophenyl)-3,4-dihydro-2H-1,4-benzoxazin-6-ol 
• 1202503-64-7 4-(2,4-dichlorophenyl)-3,4-dihydro-2H-1,4-benzoxazin-6-yl trifluoromethanesulfonate 
• 1202503-61-4 4-(2,4-dichlorophenyl)-6-methoxy-3,4-dihydro-2H-1,4-benzoxazine 

Relevant articles and documents

TRICYCLIC FURAN-SUBSTITUTED PIPERIDINEDIONE COMPOUND

Disclosed are a series of tricyclic furan-substituted piperidinedione compounds and an application thereof in preparing a drug for treating a disease related to CRBN protein. In particular, disclosed is a derivative compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

Synthesis, docking, 3-D-qsar, and biological assays of novel indole derivatives targeting serotonin transporter, dopamine D2 receptor, and mao-a enzyme: In the pursuit for potential multitarget directed ligands

A series of 27 compounds of general structure 2,3-dihydro-benzo[1,4]oxazin-4-yl)-2-{4-[3-(1H-3indolyl)-propyl]-1-piperazinyl}-ethanamides, Series I: 7(a-o) and (2-{4-[3-(1H-3-indolyl) -propyl]-1-piperazinyl}-acetylamine)-N-(2-morfolin-4-yl-ethyl)-fluorinated benzamides Series II: 13(a-l) were synthesized and evaluated as novel multitarget ligands towards dopamine D2 receptor, serotonin transporter (SERT), and monoamine oxidase-A (MAO-A) directed to the management of major depressive disorder (MDD). All the assayed compounds showed affinity for SERT in the nanomolar range, with five of them displaying Ki values from 5 to 10 nM. Compounds 7k, Ki = 5.63 ± 0.82 nM, and 13c, Ki = 6.85 ± 0.19 nM, showed the highest potencies. The affinities for D2 ranged from micro to nanomolar, while MAO-A inhibition was more discrete. Nevertheless, compounds 7m and 7n showed affinities for the D2 receptor in the nanomolar range (7n: Ki = 307 ± 6 nM and 7m: Ki = 593 ± 62 nM). Compound 7n was the only derivative displaying comparable affinities for SERT and D2 receptor (D2/SERT ratio = 3.6) and could be considered as a multitarget lead for further optimization. In addition, docking studies aimed to rationalize the molecular interactions and binding modes of the designed compounds in the most relevant protein targets were carried out. Furthermore, in order to obtain information on the structure-activity relationship of the synthesized series, a 3-D-QSAR CoMFA and CoMSIA study was conducted and validated internally and externally (q2 = 0.625, 0.523 for CoMFA and CoMSIA and r2ncv = 0.967, 0.959 for CoMFA and CoMSIA, respectively).

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.